Itrakonazol Stada

Itraconazole, the active ingredient in Itrakonazol Stada, is a systemic azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including dermatophytosis, candidiasis, and invasive molds, in adult patients as prescribed by a clinician.

GNH USA supplies Itrakonazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution globally efficiently.

Itraconazole is used systemically to treat a variety of fungal infections affecting the skin, mucous membranes and internal organs.

- Dermatophytosis: effective in treating skin and nail infections caused by dermatophyte fungi. - Candidiasis: used for oral, esophageal and systemic Candida infections. - Aspergillosis: indicated for invasive disease caused by Aspergillus species. - Blastomycosis: employed in the management of infections caused by Blastomyces dermatitidis. - Histoplasmosis: treats disseminated disease due to Histoplasma capsulatum.

Adverse reactions may occur with itraconazole therapy and vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: skin erythema or mild itching. - Taste disturbance: altered or reduced taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or severe liver injury. - Cardiac failure: worsening of pre‑existing heart conditions. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Anaphylaxis: rare but potentially life‑threatening allergic reaction.

Before initiating therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline enzymes and repeat during treatment. - Cardiac assessment: avoid in patients with known heart failure. - Drug hypersensitivity: discontinue if signs of allergic reaction appear. - Concomitant medications: review for agents that may increase itraconazole levels. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Itraconazole has a notable potential for drug‑drug interactions due to CYP3A4 inhibition and other mechanisms.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may cause toxic itraconazole levels. - Certain statins (simvastatin, lovastatin): increased risk of myopathy. - QT‑prolonging agents (e.g., quinidine, sotalol): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may reduce itraconazole efficacy. - Oral contraceptives: efficacy may be decreased, consider additional contraception. - Warfarin: monitor INR closely for potential anticoagulant effect changes.